Short $FND as management repeatedly misled on comp trends; actual declines (Q3 -9%, Q4 guided -12-15%) confirm structural weakness after four consecutive years of negative comps.
Short medtech stocks/ETF as the speaker expects further multiples compression tomorrow, driven by a directional bearish view on the sector's valuation.
Short medtech stocks/ETF as the speaker expects further multiples compression tomorrow, driven by a directional bearish view on the sector's valuation.
Short medtech stocks/ETF as the speaker expects further multiples compression tomorrow, driven by a directional bearish view on the sector's valuation.
Buy FICO on oversold conditions with management signaling stock too cheap sub-$1200 and an annualized buyback rate of 10% of shares outstanding as a catalyst.
Buy AMZN because its pharmacy expansion leverages existing same-day delivery logistics and One Medical's digital script capabilities to capture consumer healthcare spend and data, starting with GLP-1 medications.
Buy ISRG as Q1 results show strong margin expansion and record buybacks, while the stock trades at a historically low forward P/E with an AI-enabled product catalyst on the horizon.
Long DIM.FP due to strong order growth in bioprocessing equipment (>30% in Q1), indicating a sustained recovery and acceleration in the bioprocessing thematic.
Buy MSFT as its Azure/CoPilot evolution into a reliable, secure, multimodal product will drive future enterprise adoption and revenue growth, overcoming current performance issues.
Short NYT due to deteriorating fundamental data trends, specifically a 20% drop in gross additions and rising churn, alongside significant insider selling by the CEO and CFO.